Time for weighing things up for Kare Schultz, Teva CEO: group gains $8bn in capitalization in two months

It is already time for weighing things up for Kare Schultz, Teva’s new CEO. The Danish manager has been leading the Israel-based group for two months now and has been forced to announce very negative quarter results–on November 2th–and to announce a plan to cut 14,000 jobs globally. Kare Schultz has succeeded to revamp the dismissal process for certain assets and to give a new structure to the group of executives part of Teva’s board. Teva’s shares (Wall Street) have increased from $11 to $19, taking the group’s capitalization by $8bn to $19bn, which confirms that Teva ranks second after Check Point Software (Nasdaq), which has a capitalization of $16.8bn.